pain management
Pain not being managed with scattergun approach
Prescribers are handing out ‘Endone like lollies’ but pain management remains inadequate, says a pain expert—but pharmacy can help Queensland pharmacist Karalyn Huxhagen, winner of the 2015 PSA Award for …
Opioid misuse: ‘Endone has become the new Panadol.’
In hospitals Endone has become the new Panadol and Australia is going down the same path as the United States when it comes to opioids, say doctors. The doctors were …
AusCann welcomes cannabis bill
Australian medicinal cannabis company AusCann has welcomed the passing of the Narcotic Drugs Amendment Bill 2016 by the Commonwealth Parliament. “We believe Australian patients have the right to access high …
QUM Award for pain management: nominations open
The PSA has announced that nominations are open for an educational grant to be awarded to an Australian pharmacist who has made an outstanding contribution to the Quality use of …
Opioid use quadruples in Australia, but others can’t access pain relief
Use of common opioid painkillers such as codeine, morphine and oxycodone has more than quadrupled in Australia over the past decade and doubled worldwide over the same period a report …
Reconsider Panadol Osteo delisting in light of risks: Painaustralia
The PBS delisting of Panadol Osteo needs to be reconsidered in the light of cost and clinical safety implications, says Painaustralia. The organisation has highlighted the risk of adverse clinical …
TGA seeks submissions on codeine options
The TGA is seeking further advice and submissions from stakeholders in regard to newly proposed options for the future scheduling of OTC codeine-containing preparations. Last month it deferred its final …
Time allows Regulation Impact Statement on codeine: PSA
The Pharmaceutical Society of Australia has welcomed the deferral of a final decision on the possible rescheduling of codeine. PSA National President, Joe Demarte says that the extra time allowed …
Stakeholders gear up on real-time codeine monitoring
The deferment of a final decision on the upscheduling of codeine-containing OTCs is very good news, but stakeholders now need to get moving quickly on the proposed real-time monitoring system …
Codeine stays OTC… for now
Over-the-counter medicines containing codeine will remain OTC until at least 2017, the TGA has announced. A delegate of the Secretary to the Department of Health gave notice of the deferment …
Upscheduling codeine could have migraine silver lining
There’s been a lot of debate on upscheduling codeine, writes Phil Spyrou, but if it happens, pharmacists will have an opportunity to help migraine sufferers The final decision on whether …
Codeine crackdown could cost $1.27 billion over four years… and more
Upscheduling codeine-containing OTCs could cost upwards of $1.27 billion in MBS outlay alone over the next four years, a new report has found. The Pharmacy Guild engaged Cadence Economics to …